<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BAYCADRON- dexamethasone elixir </strong><br>Wockhardt USA, LLC<br></p></div>
<h1>BAYCADRON™ ELIXIR <br>(Dexamethasone Elixir, USP <br>0.5 mg/5 mL)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">Each 5 mL (teaspoonful) contains:</span><br>Dexamethasone, USP……….……….…………………………. 0.5 mg</p>
<p><span class="Bold">Also contains:</span><br>Benzoic Acid, USP……………………………………………….. 0.1%<br>  (as preservative)<br>
Alcohol……………………………………………………………. 5.1%</p>
<p><span class="Bold">Inactive Ingredients:</span> Artificial Raspberry Flavor; Citric Acid, USP; FD&amp;C Red No. 40; Liquid Sugar; Propylene Glycol, USP and Purified Water, USP. <span class="Bold">It may also contain</span> Sodium Citrate, USP.</p>
<p>Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. </p>
<p>Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water. The molecular weight is 392.47. It is designated chemically as 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione. The molecular formula is C<span class="Sub">22</span>H<span class="Sub">29</span>FO<span class="Sub">5</span> and the structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e59d3b87-af2e-4262-b89d-e95aa79f11b7&amp;name=baycadron-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, including dexamethasone, are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.</p>
<p>Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.</p>
<p>At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>1.	<span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></h2>
<p class="First">Primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).</p>
<dl>
<dt> </dt>
<dd>Congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></dd>
<dt> </dt>
<dd>Nonsuppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> associated with cancer</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>2.	Rheumatic Disorders</h2>
<p class="First">As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:</p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">Psoriatic arthritis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases may require low-dose maintenance therapy)</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing spondylitis</span></dd>
<dt> </dt>
<dd>Acute and subacute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span></dd>
<dt> </dt>
<dd>Acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span></dd>
<dt> </dt>
<dd>Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span></dd>
<dt> </dt>
<dd>Post-traumatic <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">Synovitis</span> of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">Epicondylitis</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>3.	Collagen Diseases</h2>
<p class="First">During an exacerbation or as maintenance therapy in selected cases of:</p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span></dd>
<dt> </dt>
<dd>Acute rheumatic carditis</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>4.	Dermatologic Diseases</h2>
<p class="First"></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">Pemphigus</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis</dd>
<dt> </dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>)</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">Mycosis fungoides</span></dd>
<dt> </dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></dd>
<dt> </dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5"></a><p></p>
<h2>5.	Allergic States</h2>
<p class="First">Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:</p>
<dl>
<dt> </dt>
<dd>Seasonal or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>	</dd>
<dt> </dt>
<dd>Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic dermatitis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">Drug hypersensitivity</span> reactions</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6"></a><p></p>
<h2>6.	Ophthalmic Diseases</h2>
<p class="First">Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as:</p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">Allergic conjunctivitis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></dd>
<dt> </dt>
<dd>Allergic corneal marginal <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span> ophthalmicus</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span> and <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="434033" conceptname="Chorioretinitis">Chorioretinitis</span></dd>
<dt> </dt>
<dd>Anterior segment <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span></dd>
<dt> </dt>
<dd>Diffuse posterior <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> and choroiditis</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span></dd>
<dt> </dt>
<dd>Sympathetic ophthalmia</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.7"></a><p></p>
<h2>7.	Respiratory Diseases</h2>
<dl>
<dt> </dt>
<dd>Symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span></dd>
<dt> </dt>
<dd>Loeffler's syndrome not manageable by other means</dd>
<dt> </dt>
<dd>Berylliosis</dd>
<dt> </dt>
<dd>Fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate antituberculous chemotherapy</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonitis</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.8"></a><p></p>
<h2>8.	Hematologic Disorders</h2>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span> in adults</dd>
<dt> </dt>
<dd>Secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in adults</dd>
<dt> </dt>
<dd>Acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span></dd>
<dt> </dt>
<dd>Erythroblastopenia (RBC <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</dd>
<dt> </dt>
<dd>Congenital (erythroid) <span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">hypoplastic anemia</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.9"></a><p></p>
<h2>9.	Neoplastic Diseases</h2>
<p class="First">For palliative management of:</p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> in adults</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">Acute leukemia</span> of childhood</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.10"></a><p></p>
<h2>10.	Edematous States</h2>
<p class="First">To induce a <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in the <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, without <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, of the idiopathic type or that due to <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.11"></a><p></p>
<h2>11.	Gastrointestinal Diseases</h2>
<p class="First">To tide the patient over a critical period of the disease in:</p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative colitis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">Regional enteritis</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.12"></a><p></p>
<h2>12.	Miscellaneous</h2>
<dl>
<dt> </dt>
<dd>Tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy</dd>
<dt> </dt>
<dd>Trichinosis with neurologic or myocardial involvement</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.13"></a><p></p>
<h2>13. Diagnostic testing of adrenocortical hyperfunction</h2>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<dl>
<dt> </dt>
<dd>Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to this product</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.</p>
<p>Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving steroids already, dosage may have to be increased. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.</p>
<p>Corticosteroids may mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may appear during their use. There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. Moreover, corticosteroids may affect the nitroblue-tetrazolium test for <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> and produce false-negative results.</p>
<p>In <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>, a double-blind trial has shown that the use of corticosteroids is associated with prolongation of <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and a higher incidence of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>.</p>
<p>Corticosteroids may activate latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>. Therefore, it is recommended that latent or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Prolonged use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to fungi or viruses.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-5.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
<p>Corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. Mothers taking pharmacologic doses of corticosteroids should be advised not to nurse.</p>
<p>Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p>
<p>Administration of live virus vaccines, including <span class="product-label-link" type="condition" conceptid="134573" conceptname="Smallpox">smallpox</span>, is contraindicated in individuals receiving immunosuppressive doses of corticosteroids. If inactivated viral or bacterial vaccines are administered to individuals receiving immunosuppressive doses of corticosteroids, the expected serum antibody response may not be obtained. However, immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease.</p>
<p>Persons who are on drugs which suppress the immune system are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than healthy individuals. <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, for example, can have more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> develops, treatment with antiviral agents may be considered.</p>
<p>The use of Baycadron™ Elixir in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.</p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. </p>
<p>Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; therefore, therapy with corticosteroids should be used with great caution in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the <span class="product-label-link" type="condition" conceptid="4224791" conceptname="Steroid withdrawal syndrome">corticosteroid withdrawal syndrome</span> including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. This may occur in patients even without evidence of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>.</p>
<p>There is an enhanced effect of corticosteroids in patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and in those with cirrhosis.</p>
<p>Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>.</p>
<p>The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
<p>Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>.</p>
<p>Steroids should be used with caution in nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, if there is a probability of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, or other pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, fresh intestinal anastomoses, active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">Fat embolism</span> has been reported as a possible complication of <span class="product-label-link" type="condition" conceptid="195212" conceptname="Hypercortisolism">hypercortisonism</span>.</p>
<p>When large doses are given, some authorities advise that corticosteroids be taken with meals and antacids taken between meals to help to prevent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>.</p>
<p>Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.</p>
<p>Steroids may increase or decrease motility and number of spermatozoa in some patients.</p>
<p>Phenytoin, phenobarbital, ephedrine, and rifampin may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring adjustment in corticosteroid dosage. These interactions may interfere with <span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">dexamethasone suppression tests</span> which should be interpreted with caution during administration of these drugs.</p>
<p>False-negative results in the <span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">dexamethasone suppression test</span> (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be checked frequently in patients who are receiving corticosteroids and coumarin anticoagulants at the same time because of reports that corticosteroids have altered the response to these anticoagulants. Studies have shown that the usual effect produced by adding  corticosteroids is inhibition of response to coumarins, although there have been some conflicting reports of potentiation not substantiated by studies.</p>
<p>When corticosteroids are administered concomitantly with potassium-depleting diuretics, patients should be observed closely for development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.1"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Italics">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span>:</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Sodium retention</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>	</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients</dd>
<dt> </dt>
<dd>Potassium loss</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">Hypokalemic alkalosis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></dd>
</dl>
<p><span class="Italics">Musculoskeletal:</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">Steroid myopathy</span></dd>
<dt> </dt>
<dd>Loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></dd>
<dt> </dt>
<dd>Vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral    and humeral heads</dd>
<dt> </dt>
<dd>Pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span></dd>
</dl>
<p><span class="Italics">Gastrointestinal:</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span></dd>
<dt> </dt>
<dd>Perforation of the small and large bowel, particularly in patients with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></dd>
<dt> </dt>
<dd>Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span></dd>
<dt> </dt>
<dd>Ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span></dd>
</dl>
<p><span class="Italics">Dermatologic:</span></p>
<dl>
<dt> </dt>
<dd>Impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing</dd>
<dt> </dt>
<dd>Thin fragile skin</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></dd>
<dt> </dt>
<dd>Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
<dt> </dt>
<dd>May suppress reactions to skin tests</dd>
<dt> </dt>
<dd>Other cutaneous reactions, such as <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span></dd>
</dl>
<p><span class="Italics">Neurologic:</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) usually after treatment</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">Psychic Disturbances</span></dd>
</dl>
<p><span class="Italics">Endocrine:</span></p>
<dl>
<dt> </dt>
<dd>Menstrual irregularities</dd>
<dt> </dt>
<dd>Development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> state</dd>
<dt> </dt>
<dd>Suppression of growth in children</dd>
<dt> </dt>
<dd>Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or illness</dd>
<dt> </dt>
<dd>Decreased carbohydrate tolerance</dd>
<dt> </dt>
<dd>Manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus</dd>
<dt> </dt>
<dd>Increased requirements for insulin or oral hypoglycemic agents in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> </dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span></dd>
</dl>
<p><span class="Italics">Ophthalmic:</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">Posterior subcapsular cataracts</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Increased intraocular pressure</span>	</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span></dd>
</dl>
<p><span class="Italics">Metabolic:</span></p>
<dl>
<dt> </dt>
<dd>Negative nitrogen balance due to protein catabolism</dd>
</dl>
<p><span class="Italics">Cardiovascular:</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">Myocardial rupture</span> following recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>)</dd>
</dl>
<p><span class="Italics">Other:</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccups</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Reports of acute toxicity and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> following overdosage of glucocorticoids are rare. In the event of overdosage, no specific antidote is available; treatment is supportive and symptomatic.</p>
<p>The oral LD<span class="Sub">50</span> of dexamethasone in female mice was 6.5 g/kg.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>For oral administration</h2>
<p class="First">DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT.</p>
<p>The initial dosage varies from 0.75 to 9 mg a day depending on the disease being treated. In less severe diseases doses lower than 0.75 mg may suffice, while in severe diseases doses higher than 9 mg may be required. The initial dosage should be maintained or adjusted until the patient's response is satisfactory. If satisfactory clinical response does not occur after a reasonable period of time, discontinue Baycadron™ Elixir and transfer the patient to other therapy.</p>
<p>After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.</p>
<p>Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>). During stress it may be necessary to increase dosage temporarily.</p>
<p>If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually.</p>
<p>The following milligram equivalents facilitate changing to Baycadron™ Elixir from other glucocorticoids:</p>
<table width="100%">
<col align="center" valign="bottom" width="18%">
<col align="center" valign="bottom" width="24%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="18%">
<thead><tr class="First Last">
<th class="Lrule" align="center">BAYCADRON™ ELIXIR</th>
<th class="Lrule" align="center">METHYLPREDNISOLONE AND TRIAMCINOLONE</th>
<th class="Lrule" align="center">PREDNISOLONE<br>AND<br>PREDNISONE</th>
<th class="Lrule" align="center">HYDROCORTISONE</th>
<th class="Lrule Rrule" align="center">CORTISONE</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule" align="center">0.75 mg =</td>
<td class="Lrule" align="center">4 mg =</td>
<td class="Lrule" align="center">5 mg =</td>
<td class="Lrule" align="center">20 mg =</td>
<td class="Lrule Rrule" align="center">25 mg</td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">Dexamethasone suppression tests</span></h2>
<ol>
<li>Tests for Cushing's syndrome.<br>Give 1 mg of Dexamethasone orally at 11:00 p.m. Blood is drawn for plasma cortisol determination at 8:00 a.m. the following morning.<br>For greater accuracy, give 0.5 mg of Dexamethasone orally every 6 hours for 48 hours. Twenty-four hour urine collections are made for determination of 17-hydroxycorticosteroid excretion. </li>
<li>Test to distinguish Cushing's syndrome due to pituitary ACTH excess from Cushing's syndrome due to other causes.<br>Give 2 mg of Dexamethasone orally every 6 hours for 48 hours. Twenty-four hour urine collections are made for determination of 17-hydroxycorticosteroid excretion.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Baycadron™ Elixir (Dexamethasone Elixir, USP 0.5 mg/5 mL) is supplied as a clear, red, raspberry-flavored liquid in the following size:</p>
<p>8 fl oz (No Dropper) (237 mL)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<h2>RECOMMENDED STORAGE</h2>
<p class="First"><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled RoomTemperature].</span></p>
<p><span class="Bold">KEEP TIGHTLY CLOSED</span></p>
<p><span class="Bold">AVOID FREEZING</span></p>
<p>Dispense in a tight container as defined in the USP.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>Product No.: 8810</p>
<p><span class="Bold">Manufactured For:<br>
						Wockhardt USA, LLC<br>Parsippany, NJ 07054</span></p>
<p><span class="Bold">Manufactured By:<br>Morton Grove Pharmaceuticals, Inc.<br>Morton Grove, IL 60053</span></p>
<p>28810<br>ISS. 12-08</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 30 mL Bottle</h1>
<p class="First"><span class="Bold Italics">WOCKHARDT</span></p>
<p><span class="Bold">NDC 64679-810-30</span></p>
<p><span class="Bold">BAYCADRON™<br>ELIXIR</span></p>
<p><span class="Bold">(Dexamethasone Elixir,<br>USP 0.5 mg/5 mL)</span></p>
<p><span class="Bold">PROFESSIONAL SAMPLE –<br>NOT FOR RESALE</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">NET: 1 fl oz (30 mL)</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30 mL Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e59d3b87-af2e-4262-b89d-e95aa79f11b7&amp;name=baycadron-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BAYCADRON 		
					</strong><br><span class="contentTableReg">dexamethasone elixir</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64679-810</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dexamethasone</strong> (Dexamethasone) </td>
<td class="formItem">Dexamethasone</td>
<td class="formItem">0.5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>raw sugar</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzoic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Anhydrous Citric Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C red no. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (Clear) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64679-810-08</td>
<td class="formItem">30 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA088254</td>
<td class="formItem">07/27/1983</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Wockhardt USA, LLC
							(170508365)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5f296c99-aae6-4348-bdbd-b1fa3e2678d1</div>
<div>Set id: e59d3b87-af2e-4262-b89d-e95aa79f11b7</div>
<div>Version: 4</div>
<div>Effective Time: 20090715</div>
</div>
</div> <div class="DistributorName">Wockhardt USA, LLC</div></p>
</body></html>
